Sonoma Pharmaceuticals Announces Licensing of Antimicrobial Hypochlorous Acid Solution for Management of Blepharitis in the Spanish/Portuguese Markets to Brill Pharma, S.L.
September 26, 2018 07:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company that develops and markets unique and effective solutions for the...
Sonoma Pharmaceuticals Appoints Phillipe Weigerstorfer to Board of Directors
September 19, 2018 07:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced the appointment of Philippe Weigerstorfer to the company’s board of directors. ...
Sonoma Pharmaceuticals Announces Results from Study of Sonoma’s Performance-Stabilized HOCl™ (Hypochlorous Acid) in Management of Acne Vulgaris
August 28, 2018 07:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced that results from a study into the use of the company’s proprietary high-strength...
Sonoma Pharmaceuticals Reports First Quarter FY 2019 Financial Results
August 08, 2018 16:05 ET
|
Sonoma Pharmaceuticals, Inc.
Total Revenue up 20% over March 2018 Quarter Total Revenue up 14% over June 2017 Quarter Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sonoma...
Sonoma Pharmaceuticals Announces First Quarter FY 2019 Financial Results and Conference Call
July 25, 2018 07:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA) today announced that financial results for its fiscal year 2019 first quarter, ended June 30, 2018,...
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2018 Financial Results
June 13, 2018 16:05 ET
|
Sonoma Pharmaceuticals, Inc.
Strong Annual Year-Over-Year Growth in Revenue of 30%$10 Million in Cash as of March 31, 2018 Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif., June 13, 2018 (GLOBE NEWSWIRE) -- Sonoma...
U.SK, dermatology arm of Brazilian NC Group, and Sonoma Pharmaceuticals Enter into License Agreement for Exclusive Rights to Sonoma’s Dermatology Products in Brazil
June 05, 2018 07:05 ET
|
Sonoma Pharmaceuticals, Inc.
SAO PAULO, Brazil and PETALUMA, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- U.SK Dermatology, the dermatology arm of NC Group, which besides other businesses is the largest pharmaceutical organization...
Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2018 Financial Results and Conference Call
May 31, 2018 07:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., May 31, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), today announced that financial results for its fiscal fourth quarter 2018, ended March 31, 2018, will...
Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer
May 08, 2018 07:00 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a specialty pharmaceutical company that develops and markets unique and effective dermatological...
Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products
April 17, 2018 07:04 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...